. Dig Liver Dis. 2008 Jul;40 Suppl 2:S260-4.Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V,de'Angelis GL, Federici T.Division Pediatric Gastroenterology and Hepatology, Department of Pediatrics,University of Rome "La Sapienza", Rome, Italy. firstname.lastname@example.orgBACKGROUND: Infliximab (IFX), the chimeric anti TNFalpha antibody, an establishedtreatment for Crohn's disease in adults and in children, is used less frequently in ulcerative colitis (UC).AIM OF THE STUDY: To report the clinical course of pediatric patients with activeUC receiving IFX.PATIENTS AND METHODS: Charts of 22 patients were reviewed (13 male, 9 female): 4 with a severe UC attack refractory to systemic corticosteroids (CS); 18 with aprotracted course, of which 16 CS-dependent and 2 CS-resistant. The baselinetherapeutic program consisted of 3 consecutive intravenous infusions (0, 2, 6weeks) of IFX (5 mg/kg), followed by a retreatment schedule (infusion every 8weeks); azathioprine (AZA) was administered chronically in all. Clinicalevaluation was done with the Lichtiger Colitis Activity Index (LCAI). Follow-upwas performed until week 54. LCAI >/= 9 was considered treatment failure; a LCAI </= 2 was consistent with remission.RESULTS: All 22 patients began the study with a LCAI > 9: 12 had a full response and were on remission at week 54 and did not receive CS (8 on IFX re-treatmentand AZA, 4 on AZA alone); 6 had a partial response; 4 were non responders.Colectomy was performed in 7 patients, beyond the period of the acute attack inall but one.CONCLUSIONS: In children with severe ulcerative colitis IFX is a valuabletreatment for inducing remission, avoiding emergency colectomy; retreatment maybe offered to maintain remission.
|Rivista||Digestive and Liver Disease|
|Stato di pubblicazione||Published - 2008|
All Science Journal Classification (ASJC) codes